Latest Capital Raising News

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Skylark Minerals has reshaped its leadership team with seasoned gold industry veterans and agreed to divest its Citronen Zn-Pb Project, positioning the company for renewed growth and exploration success.

Lykos Metals Limited narrows its Sockovac project tenement while securing an extended exploration permit for Jezero, positioning itself for focused growth in Bosnia and Herzegovina.

Rox Resources has completed its $27 million capital raising with the final tranche of shares issued to institutional investors and company directors, signaling strong backing for its growth plans.

Arrow Minerals has secured $7 million through a well-supported placement to advance its flagship Niagara Bauxite and Simandou North Iron projects in Guinea, setting the stage for key resource milestones and development studies.

I Synergy Group Limited has successfully completed a $100,000 private placement at a 16.67% discount, aiming to bolster its growth and working capital. The move signals investor confidence as the technology company advances its digital solutions agenda.

Terra Metals has secured an option to acquire a large tenement package adjacent to its flagship Dante Project, significantly expanding its exploration potential in Western Australia's West Musgrave region.

Nelson Resources bolstered its balance sheet with a $2.3 million placement and appointed Dr Louis Bucci as Executive Director, setting the stage for renewed exploration at its Fortnum and Yarri gold projects in early 2025.

Waratah Minerals Limited reported a $2.01 million net cash outflow from operating activities in the December 2024 quarter, ending with $4.23 million in cash and equivalents. The company continues its exploration efforts but faces notable cash burn that may pressure future funding.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Agrimin Limited's latest quarterly cash flow report reveals a significant reduction in cash reserves alongside ongoing operational expenditures, prompting plans for further capital raising to maintain project momentum.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.